Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;17(1):59-68.
doi: 10.1007/s11764-022-01301-0. Epub 2022 Dec 1.

Associations among hearing loss, multiple co-occurring symptoms, and quality of life outcomes in cancer survivors

Affiliations

Associations among hearing loss, multiple co-occurring symptoms, and quality of life outcomes in cancer survivors

Christine Miaskowski et al. J Cancer Surviv. 2023 Feb.

Abstract

Purpose: Evaluate for differences in demographic and clinical characteristics, occurrence of common symptoms, symptom severity scores, and quality of life (QOL) outcomes in survivors with (n = 155) and without (n = 118) audiometrically confirmed hearing loss.

Methods: Survivors, who were recruited from throughout the San Francisco Bay area, completed the self-report questionnaires to obtain the information of demographic and clinical characteristics; the occurrence and severity of depression, anxiety, fatigue, decrements in energy, sleep disturbance, pain, and cognitive impairment; and the general and cancer-specific QOL outcomes. Parametric and non-parametric tests were used to evaluate for differences between the two survivor groups.

Results: Survivors with audiometrically confirmed hearing loss were older, more likely to be male, were more likely to be unemployed, report a lower annual household income, and had a higher comorbidity burden. Except for the severity of worst pain, no between-group differences were found in the occurrence rates for or severity of any of the symptoms. Survivors with hearing loss reported worse physical function and general health scores.

Conclusions: While no between-group differences in symptom occurrence rates and severity scores were found, across the total sample, a relatively high percentage of survivors who were over 6 years from their cancer diagnosis reported clinically meaningful levels of depression (25%), anxiety (50%), fatigue (40%), decrements in energy (70%), sleep disturbance (58%), cognitive impairment (57%), and pain (60%).

Implications for cancer survivors: Clinicians need to perform routine assessments of hearing loss, as well as common co-occurring symptoms and initiate individualized symptom management interventions.

Keywords: Cancer; Chemotherapy; Depression; Fatigue; Hearing loss; Patient-reported outcomes; Quality of life; Sleep disturbance; Symptoms.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Similar articles

Cited by

References

    1. Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409–436. doi: 10.3322/caac.21731. - DOI - PubMed
    1. Desforges AD, Hebert CM, Spence AL, Reid B, Dhaibar HA, Cruz-Topete D, et al. Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: an update. Biomed Pharmacother. 2022;147:112671. doi: 10.1016/j.biopha.2022.112671. - DOI - PMC - PubMed
    1. Romano A, Capozza MA, Mastrangelo S, Maurizi P, Triarico S, Rolesi R, et al. Assessment and management of platinum-related ototoxicity in children treated for cancer. Cancers. 2020;12(5). 10.3390/cancers12051266. - PMC - PubMed
    1. Biro K, Noszek L, Prekopp P, Nagyivanyi K, Geczi L, Gaudi I, et al. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission. Oncology. 2006;70(3):177–184. doi: 10.1159/000093776. - DOI - PubMed
    1. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer. 1998;77(8):1355–1362. doi: 10.1038/bjc.1998.226. - DOI - PMC - PubMed

Publication types